Stock HLN HALEON PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Haleon plc

Equities

HLN

GB00BMX86B70

Market Closed - London S.E.
Other stock markets
 11:35:01 2024-04-26 am EDT 		5-day change 1st Jan Change
334.4 GBX +0.87% Intraday chart for Haleon plc +2.64% +3.96%
Apr. 25 Moody’s Affirms Haleon’s Ratings on Strong Operating Performance MT
Apr. 24 Haleon: a new CFO at the end of October CF

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • With an enterprise value anticipated at 3.35 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last few months, analysts have been revising downwards their earnings forecast.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HALEON PLC Stock Haleon plc
+3.96% 38.04B
B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.46% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. HLN Stock
  4. Ratings Haleon plc